A Week of Tamsulosin Buys a Bigger Sheath. It Also Costs a Week She Doesn't Have.
Preoperative tamsulosin measurably improves access-sheath placement in trial after trial. The comparator in most of those trials is no drug at all, not a patient whose actual calendar makes a week's delay its own kind of cost.
Sofia L., a 29-year-old woman, is getting married in three weeks, a date she mentioned before the referring physician had finished explaining why she was being sent to urology at all. A 6mm proximal ureteral stone has been causing intermittent colic for the past month, not severe enough to be an emergency but persistent enough that she wants it handled before, not during, a honeymoon in a country she's already researched for stone-forming risk factors (hot climate, limited access to imaging). She's otherwise healthy, has never had a stone before, drinks less water than she knows she should during her long shifts as a labor-and-delivery nurse, and asked directly, twice, how soon this could be done.
The urologist's default plan for a primary, unstented ureteroscopy — going straight for definitive treatment without a prior stenting procedure — is a week of preoperative tamsulosin to improve the odds of placing a larger ureteral access sheath on the first attempt. The trial evidence for this is real and it is narrow. Nam and colleagues' double-blinded, placebo-controlled trial in Investigative and Clinical Urology randomized two hundred patients to tamsulosin or placebo starting one week before surgery, and found successful deployment of a 12 to 14F access sheath in 88.0% against 75.3%, p of 0.038 — a genuine difference, and the reason the week exists at all is simply that this is when the trial started dosing. The same trial found no benefit at all on stent symptoms afterward. So what a week buys Sofia is a better chance at the larger sheath, and nothing else. Whether a 6mm stone needs the larger sheath is the question nobody in the room has actually asked her yet.
Consult visit, three weeks out
Nam's randomized, placebo-controlled trial found preoperative tamsulosin took successful 12 to 14F access sheath deployment from 75.3% to 88.0%. That's a real thirteen points, and it's the most evidence-supported path to getting this done in one procedure rather than two.
Seven days of tamsulosin, then proceed. I'd rather she have the best odds of one successful surgery than rush into a higher chance of an aborted attempt.
The evidence you're citing is real, and I'm not disputing the numbers. But Sofia has been explicit, twice now, about her timeline — a week of pretreatment plus the procedure itself starts crowding a wedding she's planned around, not incidentally.
This isn't a safety question with one correct answer the way an antibiotic choice might be. It's a genuine trade between procedural success rate and what she's telling us actually matters to her. I think that trade is hers to make, with the real numbers in front of her, not something we default past.
Both of you are right about what the trial shows and about what matters to Sofia — what I'd add is where in the data that benefit actually sits.
Nam's outcome measure was deployment of the LARGER sheath, and the trial's own conclusion was that preoperative tamsulosin improves success of larger-sized access sheaths — not that it improves ureteroscopy generally. A 6mm stone doesn't require maximal sheath size to achieve definitive laser lithotripsy the way a larger stone burden might. That narrows how much this specific patient, with this specific stone, is actually giving up by skipping the week.
If Sofia wants to proceed today with a smaller sheath and accept a somewhat higher chance of a staged approach if access fails, that's a reasonable trade for a stone this size — not a corner being cut.
Sofia chose to proceed today, without the week of tamsulosin pretreatment, after being told directly what the trial data suggests she's trading away — a somewhat higher chance of needing a smaller sheath or a staged, two-step approach if primary access fails. She was clear that the timeline mattered more to her than optimizing for the single-attempt success rate.
Not agreed: the Urologist would still have preferred the pretreatment course as the more evidence-supported default, and said so directly rather than simply deferring. That disagreement wasn't resolved by the decision — it was named, and Sofia's stated preference carried the day.